Annals of Clinical and Translational Neurology (May 2021)

Exploring triheptanoin as treatment for short chain enoyl CoA hydratase deficiency

  • Kristin Engelstad,
  • Rachel Salazar,
  • Dorcas Koenigsberger,
  • Erin Stackowtiz,
  • Susan Brodlie,
  • Melanie Brandabur,
  • Darryl C. De Vivo

DOI
https://doi.org/10.1002/acn3.51359
Journal volume & issue
Vol. 8, no. 5
pp. 1151 – 1157

Abstract

Read online

Abstract We explored the benefits of triheptanoin as a treatment for Short Chain Enoyl Co‐A Hydratase (SCEH) deficiency. One child with early onset, severe SCEH Deficiency was treated with triheptanoin, an odd chain oil with anapleurotic properties, for 37 months. Blood and urine chemistry safety measures, motor skills assessment, physical exam, and neurological assessment were monitored over a 27 month period. Modest sustained gains in motor skills, attention, muscle bulk, and strength were observed without any significant adverse effects. Triheptanoin appears to be a promising effective treatment for SCEH Deficiency.